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Abstract: Gestational diabetes mellitus results, in part, from a sub-optimal β-cell mass (BCM) during
pregnancy. Artemisinins were reported to increase BCM in models of diabetes by α- to β-cell
conversion leading to enhanced glucose tolerance. We used a mouse model of gestational glucose
intolerance to compare the effects of an artemisinin (artesunate) on glycemia of pregnant mice with
vehicle treatment (acetone) or no treatment. Animals were treated daily from gestational days (GD)
0.5 to 6.5. An intraperitoneal glucose tolerance test was performed prior to euthanasia at GD18.5
or post-partum. Glucose tolerance was significantly improved in both pregnant and non-pregnant
mice with both artesunate and vehicle-alone treatment, suggesting the outcome was primarily
due to the acetone vehicle. In non-pregnant, acetone-treated animals, improved glucose tolerance
was associated with a higher BCM and a significant increase in bihormonal insulin and glucagoncontaining pancreatic islet cells, suggesting α- to β-cell conversion. BCM did not differ with treatment
during pregnancy or post-partum. However, placental weight was higher in acetone-treated animals
and was associated with an upregulation of apelinergic genes. Acetone-treated animals had reduced
weight gain during treatment despite comparable food consumption to non-treated mice, suggesting
transient effects on nutrient uptake. The mean duodenal and ileum villus height was reduced
following exposure to acetone. We conclude that acetone treatment may mimic transient fasting,
resulting in a subsequent improvement in glucose tolerance during pregnancy.
Keywords: acetone; artemisinin; β-cell; islet of Langerhans; pancreas; pregnancy; glycemia
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Insulin resistance is a normal physiological feature in the third trimester of pregnancy
that requires compensatory adaptations to occur within the maternal endocrine pancreas in
order to maintain maternal euglycemia [1]. Should this compensation by the pancreatic βcell be sub-optimal, gestational diabetes mellitus (GDM) can develop. GDM is diabetes that
first appears during pregnancy and which normally regresses post-partum. Nonetheless,
GDM is associated with adverse short-term outcomes to the offspring, such as macrosomia
and respiratory distress syndrome, and longer-term issues such as childhood obesity and
adult type 2 diabetes mellitus (T2DM) [2–6]. GDM is also a risk factor for subsequent
T2DM in the mother. Current treatments for GDM, such as lifestyle behavioral change or
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administration of insulin or metformin, aim to decrease hyperglycemia but do not treat the
underlying causes including a sub-optimal β-cell mass (BCM).
A reversible expansion of pancreatic BCM and α-cell mass (ACM) has been described
in both rodents and humans, being maximal at late gestation (gestational day (GD) 18 in
rodents) [7–13]. In rodents, the changes in BCM are known to be mediated by increased
levels of placental lactogen and prolactin that initiate the proliferation of pre-existing
β-cells [13,14]. Although evidence exists to support the expansion of BCM in pregnant
humans, the mechanisms involved remain unclear [10,15]. New β-cells during pregnancy
could potentially derive from the trans-differentiation of α-cells. Previous studies in nonpregnant animals reported that α-cells can replenish β-cells during β-cell stress by α- to βcell transdifferentiation [16,17]. The use of structural analogs of artemisinins, a class of antimalarial drugs, was reported to stimulate α- to β-cell conversion in vivo and in vitro [18]
and improve glucose tolerance in non-pregnant animal models of diabetes [19,20]. The
increased BCM resulted in improved glucose homeostasis, suggesting a possible beneficial effect of treatment with artemisinins in animal models of diabetes. Nonetheless,
no data exist in hyperglycemic pregnancy. In this study, we investigated the effects of
artemisinin treatment in a mouse model of gestational glucose intolerance during and
following pregnancy [12]. Our hypothesis was that treatment with artesunate would improve glucose tolerance during pregnancy, as was observed in previous studies in diabetic
mice [21]. However, we elucidated unexpected mechanisms responsible for improved
glucose tolerance unrelated to the presence of an artemisinin.
2. Results
2.1. Artesunate Treatment in Early Gestation and Pregnancy Outcomes
We examined pregnant mice previously exposed to a maternal low protein (LP) diet
during pregnancy and lactation as a model of glucose intolerance during and following
pregnancy [12]. Maternal weight gain was significantly lower in both artesunate/acetone
and the acetone vehicle group alone compared to non-treated animals (Figure 1A). However,
artesunate/acetone-treated animals had higher food consumption compared to non-treated
animals, although this was observed only at GD2.5 and 17.5 (Figure 1B). Both treatment
groups drank an average of 4mL of solution a day during treatment (Figure 1C), which
is comparable to values for non-treated mice of between 3 and 4 mL depending on body
weight [22]. There was no difference in the number of fetuses at GD18.5 (Figure 1D).
However, placental weight was significantly higher in both artesunate/acetone and acetone
vehicle animals compared to non-treated animals (Figure 1E). Furthermore, there were no
significant differences in fetal weight between treatment groups at GD18.5 despite there
being a non-significant trend suggesting animals in the artesunate/acetone-treated group
weighed more than non-treated animals (p = 0.06) (Figure 1F).
2.2. Both Artesunate- and Acetone Vehicle-Treated Animals Have Improved Glucose Tolerance vs.
Non-Treated Females
Fasted blood glucose (4 h fast) did not significantly differ with treatments for nonpregnant, pregnant, or post-partum mice. Pregnant mice in both the artesunate/acetone
and acetone vehicle group had significantly lower blood glucose levels at 5, 15, and 30 min
during the IPGTT relative to non-treated animals at GD18.5 (Figure 2A). At 120 min, the
acetone vehicle-treated animals had significantly higher blood glucose levels compared
to non-treated animals. Furthermore, the area under the glucose tolerance curve (AUC)
was significantly lower in the artesunate/acetone and acetone vehicle groups (Figure 2B).
IPGTT glycemic excursions were also significantly lower following artesunate/acetone or
acetone vehicle treatment compared with non-treated mice in non-pregnant and PPD7.5
animals (Figure 2C,E), as were the AUC values (Figure 2D,F), leading to the conclusion
that the acetone vehicle was primarily responsible for improved glucose tolerance.
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2.2. Both Artesunate‐ and Acetone Vehicle‐Treated Animals Have Improved Glucose Tolerance
vs. Non‐Treated Females
Fasted blood glucose (4 h fast) did not significantly differ with treatments for non‐
pregnant, pregnant, or post‐partum mice. Pregnant mice in both the artesunate/acetone
and acetone vehicle group had significantly lower blood glucose levels at 5, 15, and 30
min during the IPGTT relative to non‐treated animals at GD18.5 (Figure 2A). At 120 min,
the acetone vehicle‐treated animals had significantly higher blood glucose levels com‐

etone or acetone vehicle treatment compared with non‐treated mice in non‐pregnant and
PPD7.5 animals (Figure 2C,E), as were the AUC values (Figure 2D,F), leading to the con‐
clusion that the acetone vehicle was primarily responsible for improved glucose tolerance.
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Figure 2. Blood glucose values during a glucose tolerance test and the resulting area under the curve (AUC) for pregnant

Figure
2. Blood glucose values during a glucose tolerance test and the resulting area under the curve
(GD 18.5, (A,B)), non-pregnant (C,D), or post-partum (E,F) mice previously treated with artesunate/acetone (square),
(AUC)
forvehicle
pregnant
(GDor18.5,
(A,B)),
non‐pregnant
or npost‐partum
(E,F)permice
previously
acetone
alone (circle),
no treatment
(triangle).
Values show (C,D),
mean ± sem.
= 4 animals at GD18.5
treatment
groupwith
and 4-5
in non-pregnant and PPD7.5
animals. acetone
* p < 0.05, **
p < 0.01, ***
p < 0.001
non-treated
vs. treatment
group.
treated
artesunate/acetone
(square),
vehicle
alone
(circle),
or no
treatment
(triangle).
# p < 0.05, ## p < 0.01 non-treated vs. vehicle by a one-way ANOVA with Tukey’s post-hoc test.
Values show mean ± sem. n = 4 animals at GD18.5 per treatment group and 4‐5 in non‐pregnant and
PPD7.5 animals. * p < 0.05, ** p < 0.01, *** p < 0.001 non‐treated vs. treatment group. # p < 0.05, ## p <
0.01 non‐treated vs. vehicle by a one‐way ANOVA with Tukey’s post‐hoc test.

2.3. Acetone Treatment Alters Pancreas Histology during and after Pregnancy
Beta‐cell mass did not differ between artesunate and vehicle‐treated mice, and data
were subsequently combined for analysis. Beta‐cell mass was significantly higher in non‐
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2.4. Acetone Treatment Causes Hyperglucagonemia during and after Pregnancy
2.4. Acetone Treatment Causes Hyperglucagonemia during and after Pregnancy
Serum insulin and glucagon were quantified from blood collected via cardiac puncture
Serum insulin and glucagon were quantified from blood collected via cardiac punc‐
at the end of the IPGTT (120 min). Serum insulin and glucagon values did not differ
ture at the end of the IPGTT (120 min). Serum insulin and glucagon values did not differ
between artesunate and vehicle-treated mice, and data were combined for analysis in this
between artesunate and vehicle‐treated mice, and data were combined for analysis in this
and subsequent studies. There were no significant differences in serum insulin between
and subsequent studies. There were no significant differences in serum insulin between
treatment groups over time (Figure 4A). However, serum glucagon levels were significantly
treatment groups over time (Figure 4A). However, serum glucagon levels were signifi‐
higher at GD18.5 and PPD7.5 in acetone-treated animals compared to non-treated animals
cantly higher at GD18.5 and PPD7.5 in acetone‐treated animals compared to non‐treated
(Figure 4B). There were no significant differences in the serum insulin to glucagon ratio
animals (Figure 4B). There were no significant differences in the serum insulin to glucagon
between treatment groups over time (Figure 4C).
ratio between treatment groups over time (Figure 4C).
2.5. Acetone Treatment Increases Placental Apelinergic Gene Expression
To investigate a potential mechanism of improved glucose tolerance in pregnant
acetone-treated animals, we analyzed the placenta, since placental weight was higher in
acetone-treated animals (Figure 1E). Considering the placenta secretes apelin and apela
which are known to alter β-cell number we examined the expression of the apelinergic sys-
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tem. Relative Aplnr (Figure 6A) and Apela (Figure 6B) mRNA levels were both significantly
higher in acetone-treated animals compared to non-treated mice.
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2.5. Acetone Treatment Increases Islet Bihormonal Cell Number
To investigate a potential mechanism underpinning the new β‐cells observed in non‐
pregnant acetone‐treated animals, we quantified insulin and glucagon double‐positive
cells (Figure 5A,B) as a marker for possible α‐ to β‐cell trans‐differentiation. Acetone‐
treated non‐pregnant animals had significantly more bihormonal cells compared to non‐
treated animals (Figure 5C), but this was not the case for pregnant or post‐partum mice.
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2.6. Acetone Treatment Increases Placental Apelinergic Gene Expression
To investigate a potential mechanism of improved glucose tolerance in pregnant ac‐
etone‐treated animals, we analyzed the placenta, since placental weight was higher in ac‐
etone‐treated animals (Figure 1E). Considering the placenta secretes apelin and apela
which are known to alter β‐cell number we examined the expression of the apelinergic
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Figure 6. Placental mRNA expression of Aplnr (A), and Apela (B) in acetone‐treated or non‐treated pregnant mice
(GD18.5). The fold change in expression was measured relative to the housekeeping gene cyclophilin A. Median values
are shown, n = 5 non‐treated animals and 4 acetone‐treated animals. * p < 0.05, ** p < 0.01, acetone‐treated vs. water by a
one‐way ANOVA with Tukey’s post‐hoc test.

Figure 6. Placental mRNA expression of Aplnr (A), and Apela (B) in acetone-treated or non-treated
pregnant mice (GD18.5). The fold change in expression was measured relative to the housekeeping
gene cyclophilin A. Median values are shown, n = 5 non-treated animals and 4 acetone-treated
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uptake equivalent to a period of fasting. This was investigated by examining tissue mor‐
phology in two areas of the gastro‐intestinal tract, the duodenum and the ileum, in adult
female mice either 3 or 19 days after administration of acetone within drinking water.
Gross morphology of the villi did not differ following acetone treatment at either time
point, nor did the number of villi per transverse tissue section. However, the mean villus
height was significantly reduced 3 days after acetone treatment in the ileum but not in the
duodenum (Figure 7). Conversely, 19 days after treatment, the villus height had fully re‐
covered and was greater than in controls in the ileum but was significantly reduced in the
duodenum. Therefore, acetone treatment had both short‐ and long‐term effects on villus
morphology but in different regions of the gut.
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3. Discussion
by a one-way ANOVA with Tukey’s post-hoc test.
Artemisinins were shown to increase BCM via α‐ to β‐cell trans‐differentiation and
improve glucose homeostasis in non‐pregnant animal models of diabetes [18], although
these findings are controversial and have been rebutted [21,23]. Our experiments showed
a high consumption of artesunate within drinking water and no indications of fetal re‐
sorptions to implicate embryolethality. Nonetheless, the initial objective of testing ar‐
tesunate was negated as we noted that the improvement in glucose tolerance was similar
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3. Discussion
Artemisinins were shown to increase BCM via α- to β-cell trans-differentiation and
improve glucose homeostasis in non-pregnant animal models of diabetes [18], although
these findings are controversial and have been rebutted [21,23]. Our experiments showed
a high consumption of artesunate within drinking water and no indications of fetal resorptions to implicate embryolethality. Nonetheless, the initial objective of testing artesunate
was negated as we noted that the improvement in glucose tolerance was similar between
the treatment group of artesunate diluted in acetone vehicle and that of the vehicle alone,
leading us to conclude that the effect was primarily due to administration of the acetone
vehicle. Thus, we re-adjusted our focus to determine the effects of acetone on glucose
homeostasis and pancreas histology.
Weight gain was lower in acetone-treated animals during treatment, although body
weight recovered by the end of the experiment. Acetone-treated animals consumed a
comparable amount of food as non-treated animals, presenting the possibility that acetone
might have had a transient detrimental effect on nutrient uptake via the intestines, resulting
in reduced weight gain in treated animals. A previous study found that acetone abolished
the adhesion of F18-fimbriated (F18R) E. coli to isolated porcine intestinal villi in vitro,
concluding that F18R was a glycolipid [24]. Since glycosphingolipids (GSL) are a major
component of intestinal enterocytes, it is possible that acetone could be breaking down the
intestinal villi and limiting nutrient absorption. In an animal model with genetic deletion of
the gene for the enzyme that catalyzes the initial step of GSL biosynthesis (Ugcg), newborn
mice presented with growth retardation and loss of body fat deposits due to a severe
disturbance in the uptake of nutrients [25]. The same study showed that adult mice had
a drastic decrease in body weight, as was observed in our study following treatment
with acetone. It was concluded that GSLs in the intestinal epithelium are essential for
intestinal endocytic function to effectively absorb nutrients. It is worth noting that reduced
nutrient and glucose uptake for the time period of the treatment in our study could mimic
a situation of fasting, which has been suggested to have protective effects by reducing
oxidative stress, and protects against many diseases in both rodents and humans [26,27].
While the gross anatomy of the villi in the duodenum and ileum in the present study was
not altered after acetone ingestion, there were both short- and long-term effects on villus
height, suggesting a disruption to endocytic generative cycles and, potentially, function.
It is also possible that acetone crossed the gastrointestinal epithelium and altered
metabolic homeostasis at peripheral tissues. Orally administered acetone is very rapidly
absorbed into the blood stream in both rodents and humans. After administration of 14 Clabelled acetone to rats by gavage once a day for 7 days, between 67 and 76% was expired as
CO2 and 7% as acetone in the urine over 24 h, indicating an absorption efficiency of around
80% [28]. Once within the blood, acetone is equally distributed within the tissues and no
immediate endocrine effects have been reported. It is possible to estimate the likely steady
state plasma levels of acetone during oral administration based on previous reports. Scholl
and Iba [29] administered 7.5% v/v acetone within drinking water for 11 days. After day
4, a plateau of plasma acetone was achieved around 1200 µg/mL. Based on the 0.4% v/v
acetone dilution used in the present study, this would equate to a plasma concentration of
around 64 µg/mL, as there is a linear correlation between acetone dosage and the amount
absorbed. However, since acetone is readily soluble in water, its absorption through the
gastrointestinal tract is compatible with impaired active epithelial transport of glucose and
other nutrients through enterocytic damage.
Further investigations of mechanisms of improved glucose tolerance in acetone-treated
animals examined changes in the endocrine pancreas. Although BCM was higher in nonpregnant acetone-treated animals compared to controls, this did not correlate with higher
serum insulin levels. Serum glucagon levels were higher at the end of the IPGTT at both
GD18.5 and PPD7.5, despite no differences being observed in ACM. Adult mice with Ugcg
gene deletion displayed severe structural defects in the small and large intestine, which
could also extend to the enteroendocrine cells [25]. The L-cells in the distal ileum and colon
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secrete glucagon-like peptide 1 (GLP-1), an incretin hormone that is released in response to
nutrient ingestion. GLP-1 increases insulin secretion and inhibits glucagon secretion [30].
The elevated levels of serum glucagon at GD18.5 and PPD7.5 could suggest damage to the
enteroendocrine cells in acetone-treated animals, thereby limiting the release of GLP-1.
As an alternate hypothesis, we quantified bihormonal (insulin and glucagon doublepositive) cells within islets as a marker for possible α- to β-cell trans-differentiation that
could contribute to an increase in BCM. There was an increased percentage of bihormonal
cells in non-pregnant acetone-treated animals compared with controls. These findings
are in agreement with those observed following transient fasting of non-pregnant mice,
where a greater number of transitional α- to β-cells were observed upon re-feeding [31],
resulting in β-cell regeneration and a rescue from diabetes. However, we previously
found that α- to β-cell trans-differentiation did not contribute to the increased BCM that
normally occurs during mouse pregnancy [32]. It is possible that the bihormonal cells
represent an intermediate stage in the functional maturation of resident β-cell progenitors,
which we previously showed to contribute to the increased BCM of pregnancy in mice [11].
Determination as to whether an increased contribution of β-cell progenitors to the improved
glycemic control following acetone exposure will require analysis much earlier in gestation.
Placentae were also analyzed as contributing to improved glucose tolerance since placental weight was higher in acetone-treated compared to non-treated animals. A previous
study showed increased deposition of glycogen in placentae from women with GDM, as
the placenta acts as a buffer for excess glucose, thereby lowering blood glucose levels in
the mother [33]. Interestingly, the apelinergic system was shown to promote the transplacental transport of glucose from mother to fetus in rat dams injected intravenously with
apelin-13 without changes to the expression of the placental glucose transporters Glut1
and Glut3 [34]. Rather, it was reported that at mid to late gestation, apelinergic signaling
increased the vasodilation of fetal arterioles and glucose transport to the fetus. In the
present study, expression levels of apelinergic genes (Apela and AplnR) were increased in
the large placentae of acetone-treated animals at GD18.5 compared to non-treated animals.
Therefore, the transfer of glucose from mother to fetus in our study could be enhanced by
upregulation of the placental apelinergic system, resulting in an improved glucose status
in the mother. The trend towards higher fetal weight in acetone-treated animals further
supports this possibility of greater transplacental glucose transfer. Apelin has also been
linked to placental growth and efficiency since fetal apelin levels were reduced following
maternal food restriction [35]. Furthermore, we recently reported a decreased presence of
the Aplnr in the endocrine pancreas in hyperglycemic mouse pregnancies, associated with
a reduced BCM, using the same model as utilized in the present study [36].
In conclusion, acetone treatment improved glucose tolerance in non-pregnant, pregnant, and post-partum mice. In non-pregnant animals, improvements in glucose tolerance
were associated with an increased BCM, possibly involving α- to β-cell conversion. However, in pregnant animals, the improved glucose tolerance could involve compensatory
mechanisms such as an upregulation of the placental apelinergic system, resulting in vasodilation and increased glucose transfer subsequently decreasing maternal blood glucose
levels. The possible interactions of these mechanisms resulting in improved glucose tolerance are shown in Figure 8. Our findings provide a potential therapeutic glucose-lowering
effect of acetone via the mimicry of short-term fasting to improve glucose tolerance, including in a model of gestational glucose intolerance. The use of oral acetone in a human
health context is not practical, especially during pregnancy, given the association with gut
epithelial damage. However, other ketones such as β-hydroxybutyrate may be worthy
of future study. In a human context, these results suggest that nutritional moderation
very early in pregnancy in women at risk of gestational diabetes may improve glucose
tolerance in third trimester, possibly due to an upregulation of the apelingeric system in
placenta, resulting in greater maternal insulin availability and increased vasodilation of
fetal arterioles and glucose transport to the fetus, thereby lowering maternal blood glucose
levels [34].
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and 488 fluorophores, respectively, along with DAPI (1:500, Thermo Fisher Scientific) to
counterstain nuclei.
Tissue sections were visualized at 20x using a Nikon Eclipse TS2R inverted microscope
(Nikon, Minato, Tokyo, Japan) with the NIS-Elements program (Nikon, Minato, Tokyo,
Japan), and images were captured and analyzed using the Cell Counter plugin in ImageJ
software. Every insulin- and glucagon-expressing cell was imaged for each section and
for each animal. Manual cell counting analysis determined the percentage of bihormonal,
Insulin+ Glucagon+ cells as a marker for α- to β-cell transitional cells [13,39–41]. To determine BCM and ACM, morphometric analysis was performed by manually measuring the
total pancreas area for each tissue section, and the relative area of β-cells and α-cells [12,42].
BCM and ACM were calculated by multiplying the total β or α-cell volume (sum of entire
β or α-cell area/surface area of the entire tissue section) by the pancreas weight. Islets were
counted per tissue section and further separated by size into small (<5000 µm2 ), medium
(5000–10,000 µm2 ), or large (>10,000 µm2 ) islets as previously described [12,35].
Sections of duodenum or ileum were stained for hematoxylin and eosin (Hematoxylin
and Eosin Stain Kit, Vector Laboratories (cat# H-3502), Burlingame, CA, USA). The height
of the villus from the base of the crypt to the tip of the villus was recorded for all villi
present in a tissue section and from two separate sections from each animal. Only complete
villi present within the transverse plane of the tissue were considered.
4.4. Serum ELISA Assays
Maternal (F1) blood serum was used to quantify insulin and glucagon using an UltraSensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL, USA) and Mouse
Glucagon ELISA kit (Crystal Chem), respectively. The insulin assay has a sensitivity of
0.05 ng/mL using a 5µL sample with precision CV ≤ 10.0%. The glucagon assay has a
sensitivity of 1.1 pg/mL using a 10uL sample with precision CV < 10%. Data were collected
using a BioRad iMark plate reader and analyzed using Microplate Manager Software.
4.5. Quantitative Polymerase Chain Reaction
Placenta samples (3-5mg) were minced with scissors in lysis buffer and Qiashredder
spin columns (Qiagen) prior to total RNA extraction using the RNeasy Plus Micro kit
(Qiagen). Total RNA (<1 µg) was extracted and reverse transcribed using iScript Reverse
Transcription Supermix (Bio-Rad Laboratories, Hercules, CA, USA). Quantitative PCR
experiments were accomplished using the 2−∆∆C T method after confirmation of parallel
PCR amplification efficiencies between each gene of interest and the housekeeping gene
Cyclophilin A (Mm02342429_g1, Applied Biosystems, Forest City, CA, USA). The apelin
receptor and apela mRNA levels were quantified using the TaqMan gene expression assay
and the TaqMan Fast Advanced Master Mix (Invitrogen, Carlsbad, CA, USA) with the
following Taqman primers: apelin receptor (Aplnr) (Mm00442191_s1, Applied Biosystems)
and Apela (Mm04278372_m1, Applied Biosystems). PCR reactions were run in triplicate
using the Quantstudio design and analysis software. Quantstudio 5 (Applied Biosystems)
was programmed with the following thermal-cycling profile: polymerase activation step at
95 ◦ C for 20 s, followed by denaturation at 95 ◦ C for 3 s, and annealing/extension at 60 ◦ C
for 30 s for 40 cycles. Levels of mRNA expression were calculated relative to those of the
housekeeping gene cyclophilin A.
4.6. Statistical Analysis
Normality of distribution for each data set was determined by the Shapiro–Wilk
test with a QQ plot. Normally distributed data are presented either as mean ± SEM, or
as box plots showing median values with the first and third quartiles representing the
minimum and maximum values. Statistical significance was analyzed using GraphPad
Prism software (Version 5.0). An unpaired two-tailed Student’s t test, one-way ANOVA, or
two-way ANOVA were applied according to the set of groups that were compared. Tukey’s
post-hoc test or a Bonferroni’s post-hoc test was performed after one-way ANOVA or
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two-way ANOVA analysis, respectively. Each animal constituted a single unit of analysis
(n). n = 4–8 animals per treatment per timepoint. Statistical significance was determined as
p < 0.05.
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